Literature DB >> 27002836

Big impact of microRNAs on central B cell tolerance.

Eric Meffre1.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27002836     DOI： 10.1038/ni.3414

Source DB:  PubMed          Journal:  Nat Immunol        ISSN： 1529-2908            Impact factor:   25.606


× No keyword cloud information.
  10 in total

1.  Predominant autoantibody production by early human B cell precursors.

Authors:  Hedda Wardemann; Sergey Yurasov; Anne Schaefer; James W Young; Eric Meffre; Michel C Nussenzweig
Journal:  Science       Date:  2003-08-14       Impact factor: 47.728

2.  Receptor editing is the main mechanism of B cell tolerance toward membrane antigens.

Authors:  Regina Halverson; Raul M Torres; Roberta Pelanda
Journal:  Nat Immunol       Date:  2004-05-23       Impact factor: 25.606

3.  In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death.

Authors:  K P Lam; R Kühn; K Rajewsky
Journal:  Cell       Date:  1997-09-19       Impact factor: 41.582

Review 4.  Receptor editing in lymphocyte development and central tolerance.

Authors:  David Nemazee
Journal:  Nat Rev Immunol       Date:  2006-10       Impact factor: 53.106

Review 5.  Origins of anti-DNA antibodies and their implications for B-cell tolerance.

Authors:  M Z Radic; M Weigert
Journal:  Ann N Y Acad Sci       Date:  1995-09-29       Impact factor: 5.691

Review 6.  The establishment of early B cell tolerance in humans: lessons from primary immunodeficiency diseases.

Authors:  Eric Meffre
Journal:  Ann N Y Acad Sci       Date:  2011-12       Impact factor: 5.691

7.  Accumulation of peripheral autoreactive B cells in the absence of functional human regulatory T cells.

Authors:  Tuure Kinnunen; Nicolas Chamberlain; Henner Morbach; Jinyoung Choi; Sangtaek Kim; Joseph Craft; Lloyd Mayer; Caterina Cancrini; Laura Passerini; Rosa Bacchetta; Hans D Ochs; Troy R Torgerson; Eric Meffre
Journal:  Blood       Date:  2012-12-05       Impact factor: 22.113

8.  B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

Authors:  Stephen L Hauser; Emmanuelle Waubant; Douglas L Arnold; Timothy Vollmer; Jack Antel; Robert J Fox; Amit Bar-Or; Michael Panzara; Neena Sarkar; Sunil Agarwal; Annette Langer-Gould; Craig H Smith
Journal:  N Engl J Med       Date:  2008-02-14       Impact factor: 91.245

9.  Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

Authors:  Jonathan C W Edwards; Leszek Szczepanski; Jacek Szechinski; Anna Filipowicz-Sosnowska; Paul Emery; David R Close; Randall M Stevens; Tim Shaw
Journal:  N Engl J Med       Date:  2004-06-17       Impact factor: 91.245

10.  The microRNA miR-148a functions as a critical regulator of B cell tolerance and autoimmunity.

Authors:  Alicia Gonzalez-Martin; Brian D Adams; Maoyi Lai; Jovan Shepherd; Maria Salvador-Bernaldez; Jesus M Salvador; Jun Lu; David Nemazee; Changchun Xiao
Journal:  Nat Immunol       Date:  2016-02-22       Impact factor: 25.606
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.